Marlous van den Braber
Overview
Explore the profile of Marlous van den Braber including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
1119
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Verhoeff J, van Asten S, Kuijper L, van den Braber M, Amstalden-van Hove E, Haselberg R, et al.
N Biotechnol
. 2024 Mar;
81:33-42.
PMID: 38493996
We report the synthesis of a novel class of metal-complexing peptide-based polymers, which we name HyperMAPs (Hyper-loaded MetAl-complexed Polymers). The controlled solid-phase synthesis of HyperMAPs' scaffold peptide provides our polymer...
2.
Dusoswa S, Verhoeff J, van Asten S, Lubbers J, van den Braber M, Peters S, et al.
Front Immunol
. 2024 Feb;
15:1343484.
PMID: 38318180
Background: Glioblastomas manipulate the immune system both locally and systemically, yet, glioblastoma-associated changes in peripheral blood immune composition are poorly studied. Age and dexamethasone administration in glioblastoma patients have been...
3.
Reijnders T, Schuurman A, Verhoeff J, van den Braber M, Douma R, Faber D, et al.
Front Immunol
. 2023 Dec;
14:1260283.
PMID: 38077404
Background: Community-acquired pneumonia (CAP) represents a major health burden worldwide. Dysregulation of the immune response plays an important role in adverse outcomes in patients with CAP. Methods: We analyzed peripheral...
4.
Voabil P, de Bruijn M, Roelofsen L, Hendriks S, Brokamp S, van den Braber M, et al.
Nat Med
. 2021 Jul;
27(7):1250-1261.
PMID: 34239134
Inhibitors of the PD-1-PD-L1 axis have been approved as therapy for many human cancers. In spite of the evidence for their widespread clinical activity, little is known about the immunological...
5.
Li H, van der Leun A, Yofe I, Lubling Y, Gelbard-Solodkin D, van Akkooi A, et al.
Cell
. 2020 May;
181(3):747.
PMID: 32359441
No abstract available.
6.
Li H, van der Leun A, Yofe I, Lubling Y, Gelbard-Solodkin D, van Akkooi A, et al.
Cell
. 2019 Jan;
176(4):775-789.e18.
PMID: 30595452
Tumor immune cell compositions play a major role in response to immunotherapy, but the heterogeneity and dynamics of immune infiltrates in human cancer lesions remain poorly characterized. Here, we identify...
7.
Blank C, Rozeman E, Fanchi L, Sikorska K, van de Wiel B, Kvistborg P, et al.
Nat Med
. 2018 Oct;
24(11):1655-1661.
PMID: 30297911
Adjuvant ipilimumab (anti-CTLA-4) and nivolumab (anti-PD-1) both improve relapse-free survival of stage III melanoma patients. In stage IV disease, the combination of ipilimumab + nivolumab is superior to ipilimumab alone...
8.
Philips D, van den Braber M, Schumacher T, Kvistborg P
Methods Mol Biol
. 2016 Oct;
1514:93-101.
PMID: 27787794
The development of peptide loaded major histocompatibility complexes (MHC) conjugated to fluorochromes by Davis and colleagues 20 years ago provided a highly useful tool to identify and characterize antigen-specific T...